This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

David R. Strayer, MD; William A. Carter, MD; Isadore Brodsky, MD; Robert M. Curley, MD; Thomas Gain, MD
Hahnemann University Institute for Cancer and Blood Diseases Philadelphia

JAMA. 1984;251(13):1682-1683.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Recently, Oberg et al¹ reported symptomatic relief of carcinoid syndrome and decreases in tumor-associated metabolic products in six of nine patients receiving 3x10⁶ to 6x10⁶ units/day of leukocyte interferon intramuscularly for three months. Interestingly, with regard to possible effects on tumor growth, they were unable to demonstrate any histological changes or decreases in tumor size.

Human interferons include proteins derived from fibroblasts and immune cells as well as those derived from leukocytes. The various molecular species differ both in regard to polypeptide sequence and carbohydrate content. Both in vitro² and in vivo³ studies indicate that these various types of interferons can demonstrate tumor cell specificity.

Report of a Case.—

We recently treated with fibroblast interferon a 51-year-old man with biopsy-proved carcinoid of the rectum with multiple liver metastases. He had no symptoms of the carcinoid syndrome, and a 24-hour urine collection was . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?